Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Section 6 of 6

References

135 sources

  1. Abraham et al. (2020) (opens in a new tab)
  2. Abraham et al. (2025) (opens in a new tab)
  3. Aguiar-Ibáñez et al. (2025) (opens in a new tab)
  4. American Cancer Society (2026) (opens in a new tab)
  5. Ang et al. (2010) (opens in a new tab)
  6. Argiris et al. (2014) (opens in a new tab)
  7. Bedi et al. (2012) (opens in a new tab)
  8. Biau et al. (2026) (opens in a new tab)
  9. Bicara Therapeutics breakthrough therapy designation announcement (2025) (opens in a new tab)
  10. Bicara Therapeutics clinical trial protocol BCA101X1101 (2024) (opens in a new tab)
  11. Bicara Therapeutics expanded access policy (opens in a new tab)
  12. Bicara Therapeutics first quarter 2026 results announcement (2026) (opens in a new tab)
  13. Bicara Therapeutics Form 10-K (2026) (opens in a new tab)
  14. Bicara Therapeutics Form 10-Q (2026) (opens in a new tab)
  15. Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025) (opens in a new tab)
  16. Bicara Therapeutics fourth quarter and full year 2025 results announcement (2026) (opens in a new tab)
  17. Bicara Therapeutics phase 3 dose and 2026 outlook announcement (2026) (opens in a new tab)
  18. Bicara Therapeutics presentation (2026) (opens in a new tab)
  19. Bicara Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
  20. Bicara Therapeutics third quarter 2026 results announcement (2026) (opens in a new tab)
  21. Bicara Therapeutics three-year overall survival announcement (2026) (opens in a new tab)
  22. Black et al. (2023) (opens in a new tab)
  23. Black et al. (2024) (opens in a new tab)
  24. Boreddy et al. (2023) (opens in a new tab)
  25. Borse et al. (2022) (opens in a new tab)
  26. Bradbury et al. (2025) (opens in a new tab)
  27. Britton et al. (2024) (opens in a new tab)
  28. Bulbul et al. (2022) (opens in a new tab)
  29. Burtness et al. (2019) (opens in a new tab)
  30. Burtness et al. (2022) (opens in a new tab)
  31. Cabezas-Camarero et al. (2025) (opens in a new tab)
  32. Cancer Genome Atlas Network (2015) (opens in a new tab)
  33. Chaturvedi et al. (2011) (opens in a new tab)
  34. Chung et al. (2025) (opens in a new tab)
  35. ClinicalTrials.gov NCT04429542 (opens in a new tab)
  36. ClinicalTrials.gov NCT04534205 (opens in a new tab)
  37. ClinicalTrials.gov NCT06064877 (opens in a new tab)
  38. ClinicalTrials.gov NCT06525220 (opens in a new tab)
  39. ClinicalTrials.gov NCT06788990 (opens in a new tab)
  40. ClinicalTrials.gov NCT06790966 (opens in a new tab)
  41. ClinicalTrials.gov NCT07276399 (opens in a new tab)
  42. ClinicalTrials.gov NCT07465276 (opens in a new tab)
  43. ClinicalTrials.gov NCT07529873 (opens in a new tab)
  44. ClinicalTrials.gov NCT07552558 (opens in a new tab)
  45. ClinicalTrials.gov NCT07807163 (opens in a new tab)
  46. Cohen et al. (2019) (opens in a new tab)
  47. Costantino et al. (2025) (opens in a new tab)
  48. Dzienis et al. (2024) (opens in a new tab)
  49. EU CTIS 2024-519654-37-00 (opens in a new tab)
  50. EU CTIS 2026-526741-10-00 (opens in a new tab)
  51. Fakhry et al. (2014) (opens in a new tab)
  52. Faquin et al. (2025) (opens in a new tab)
  53. FDA (2018) (opens in a new tab)
  54. FDA (2023) (opens in a new tab)
  55. FDA (2024) (opens in a new tab)
  56. FDA (2026) (opens in a new tab)
  57. FDA List of Cleared or Approved Companion Diagnostic Devices (2026) (opens in a new tab)
  58. FDA press announcement (2026) (opens in a new tab)
  59. Ferrarotto et al. (2025a) (opens in a new tab)
  60. Ferrarotto et al. (2025b) (opens in a new tab)
  61. Ferrarotto et al. (2026a) (opens in a new tab)
  62. Ferrarotto et al. (2026b) (opens in a new tab)
  63. Ferris et al. (2016) (opens in a new tab)
  64. Fisher et al. (2018) (opens in a new tab)
  65. Forastiere et al. (1992) (opens in a new tab)
  66. Fraslin et al. (2025) (opens in a new tab)
  67. Genmab LiGeR-HN1 interim analysis announcement (2026) (opens in a new tab)
  68. Genmab petosemtamab phase 2 update announcement (2026) (opens in a new tab)
  69. Gibson et al. (2005) (opens in a new tab)
  70. Guigay et al. (2021) (opens in a new tab)
  71. Haddad et al. (2020) (opens in a new tab)
  72. Hanna et al. (2025) (opens in a new tab)
  73. Hanna et al. (2026) (opens in a new tab)
  74. Harrington et al. (2023) (opens in a new tab)
  75. Hernando-Calvo et al. (2025) (opens in a new tab)
  76. Hihara et al. (2026) (opens in a new tab)
  77. ImClone ERBITUX prescribing information (2021) (opens in a new tab)
  78. Janot et al. (2008) (opens in a new tab)
  79. Janssen RYBREVANT FASPRO prescribing information (2026) (opens in a new tab)
  80. Johnson & Johnson OrigAMI-4 cohort 2 announcement (2026) (opens in a new tab)
  81. Johnson & Johnson OrigAMI-4 cohort 5 announcement (2026) (opens in a new tab)
  82. Johnson et al. (2020) (opens in a new tab)
  83. Kaczmar et al. (2025) (opens in a new tab)
  84. Kaczmar et al. (2026a) (opens in a new tab)
  85. Kaczmar et al. (2026b) (opens in a new tab)
  86. Kao et al. (2026) (opens in a new tab)
  87. Keam et al. (2021) (opens in a new tab)
  88. Kim et al. (2012) (opens in a new tab)
  89. Lee et al. (2020) (opens in a new tab)
  90. Lee et al. (2025) (opens in a new tab)
  91. Lewis et al. (2025) (opens in a new tab)
  92. Li et al. (2025) (opens in a new tab)
  93. Lilly ERBITUX cost information (2026) (opens in a new tab)
  94. Llop et al. (2024) (opens in a new tab)
  95. Machiels et al. (2025) (opens in a new tab)
  96. Machtay et al. (2008) (opens in a new tab)
  97. Mady et al. (2025) (opens in a new tab)
  98. Mandal et al. (2016) (opens in a new tab)
  99. Massa et al. (2019) (opens in a new tab)
  100. Massa et al. (2022) (opens in a new tab)
  101. Mauskopf et al. (2007) (opens in a new tab)
  102. Merck KEYTRUDA cost information (2026) (opens in a new tab)
  103. Merck KEYTRUDA prescribing information (2026) (opens in a new tab)
  104. Meregaglia and Cairns (2017) (opens in a new tab)
  105. Mody et al. (2021) (opens in a new tab)
  106. National Cancer Institute (2021) (opens in a new tab)
  107. National Cancer Institute Laryngeal Cancer Treatment PDQ (2025) (opens in a new tab)
  108. National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025) (opens in a new tab)
  109. National Cancer Institute Oropharyngeal Cancer Treatment PDQ (2025) (opens in a new tab)
  110. Nguyen et al. (2023) (opens in a new tab)
  111. Pfister et al. (2020) (opens in a new tab)
  112. Reverdy et al. (2023) (opens in a new tab)
  113. Rischin et al. (2022) (opens in a new tab)
  114. SEER Cancer Stat Facts Laryngeal Cancer (2026) (opens in a new tab)
  115. SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026) (opens in a new tab)
  116. Senkomago et al. (2019) (opens in a new tab)
  117. She et al. (2022) (opens in a new tab)
  118. Siegel et al. (2026) (opens in a new tab)
  119. Sullivan et al. (2014) (opens in a new tab)
  120. Sung et al. (2026) (opens in a new tab)
  121. Swiecicki et al. (2026) (opens in a new tab)
  122. Tahara et al. (2025) (opens in a new tab)
  123. Tortochaux et al. (2011) (opens in a new tab)
  124. Vermorken et al. (2008) (opens in a new tab)
  125. Wakasaki et al. (2020) (opens in a new tab)
  126. WHO Drug Information Proposed INN List 130 (2023) (opens in a new tab)
  127. WHO Drug Information Recommended INN List 92 (2024) (opens in a new tab)
  128. Wissinger et al. (2014) (opens in a new tab)
  129. Wong et al. (2026a) (opens in a new tab)
  130. Wong et al. (2026b) (opens in a new tab)
  131. Xie et al. (2026) (opens in a new tab)
  132. Ye et al. (2024) (opens in a new tab)
  133. Yilmaz et al. (2023) (opens in a new tab)
  134. Zandberg et al. (2026) (opens in a new tab)
  135. Zheng et al. (2026) (opens in a new tab)